RT Journal Article
T1 Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in Peripheral Blood and Serum as Potential Biomarkers for Patients with Metastatic Colon Cancer.
A1 Jimenez-Luna, Cristina
A1 González-Flores, Encarnación
A1 Ortiz, Raul
A1 Martínez-González, Luis J
A1 Antúnez-Rodríguez, Alba
A1 Expósito-Ruiz, Manuela
A1 Melguizo, Consolación
A1 Caba, Octavio
A1 Prados, Jose
K1 angiogenesis
K1 biomarkers
K1 circulating mRNA
K1 digital PCR
K1 liquid biopsy
K1 metastatic colon cancer
AB Genes involved in the angiogenic process have been proposed for the diagnosis and therapeutic response of metastatic colorectal cancer (CRC). This study aimed to investigate the value of PTGS2, JAG1, GUCY2C and PGF-circulating RNA as biomarkers in metastatic CRC. Blood cells and serum mRNA from 59 patients with metastatic CRC and 47 healthy controls were analyzed by digital PCR. The area under the receiver operating characteristic curve (AUC) was used to estimate the diagnostic value of each mRNA alone or mRNA combinations. A significant upregulation of the JAG1, PTGS2 and GUCY2C genes in blood cells and serum samples from metastatic CRC patients was detected. Circulating mRNA levels in the serum of all genes were significantly more abundant than in blood. The highest discrimination ability between metastatic CRC patients and healthy donors was obtained with PTGS2 (AUC of 0.984) and GUCY2C (AUC of 0.896) in serum samples. Biomarker combinations did not improve the discriminatory capacity of biomarkers separately. Analyzed biomarkers showed no correlation with overall survival or progression-free survival, but GUCY2C and GUCY2C/PTGS2 expression in serum correlated significantly with the response to antiangiogenic agents. These findings demonstrate that assessment of genes involved in the angiogenic process may be a potential non-invasive diagnostic tool for metastatic CRC and its response to antiangiogenic therapy.
SN 2077-0383
YR 2021
FD 2021-05-22
LK https://hdl.handle.net/10668/28433
UL https://hdl.handle.net/10668/28433
LA en
DS RISalud
RD Apr 6, 2025